JHLT Open最新文献

{"title":"HeartMate 3 upgrade and aortic root replacement for severe aortic insufficiency and ventricular fibrillation","authors":"Katlin T. Schmitz MD ,&nbsp;Sara S. Inglis MB, BCh, BAO ,&nbsp;Mauricio A. Villavicencio MD, MBA ,&nbsp;Adrian daSilva-deAbreu MD, MSc, PhD(c)","doi":"10.1016/j.jhlto.2024.100205","DOIUrl":"10.1016/j.jhlto.2024.100205","url":null,"abstract":"<div><div>A 31-year-old woman with left ventricular (LV) assist device (LVAD) support presented with refractory ventricular arrhythmias attributed to severe aortic insufficiency and inadequate left ventricular offloading. The patient had a history of 2 prior pump exchanges in the setting of chronic polymicrobial driveline infections and prior transcatheter aortic valve implantation (TAVI). She underwent aortic valve replacement for management of her ventricular arrythmias. Due to her complicated surgical history, right heart failure, and prolonged cardiopulmonary bypass time the surgical aortic valve replacement and HeartMate 3 upgrade was complicated, but surgery was successful with subsequent termination of her ventricular arrythmias.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100205"},"PeriodicalIF":0.0,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143372644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sotatercept Use in a Patient with Pulmonary Arterial Hypertension Undergoing Lung Transplantation","authors":"Justin P. Rosenheck ,&nbsp;Kashika Goyal ,&nbsp;Tara Fallah ,&nbsp;Pamela Burcham ,&nbsp;Kukbin Choi ,&nbsp;Matthew Henn ,&nbsp;Elie Homsy ,&nbsp;Scott Visovatti ,&nbsp;Veronica Franco","doi":"10.1016/j.jhlto.2025.100213","DOIUrl":"10.1016/j.jhlto.2025.100213","url":null,"abstract":"<div><div>Pulmonary arterial hypertension (PAH) is one of the common indications for lung transplantation. Sotatercept is a new medication with a novel mechanism of action and was recently approved for the treatment of PAH. Sotatercept is associated with significant adverse effects including thrombocytopenia and erythrocytosis which can impact outcomes of lung transplantation. This is the first described case of a patient undergoing lung transplantation while receiving sotatercept for PAH.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100213"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143183717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical course of patients relisted for orthotopic heart transplantation: A national study","authors":"David Rekhtman BS ,&nbsp;Amit Iyengar MD, MSE ,&nbsp;Nikhil Ganjoo BA ,&nbsp;Cindy Song BA ,&nbsp;Noah Weingarten MD ,&nbsp;Max Shin MD ,&nbsp;Michaela Asher MPhil ,&nbsp;John DePaolo MD, PhD ,&nbsp;Marisa Cevasco MD, MPH ,&nbsp;Pavan Atluri MD","doi":"10.1016/j.jhlto.2024.100173","DOIUrl":"10.1016/j.jhlto.2024.100173","url":null,"abstract":"<div><h3>Background</h3><div>The clinical course in patients relisted for heart transplant at a different transplant center is poorly understood. We sought to describe the baseline characteristics, outcomes, and hospital selection of relisted patients by comparing their clinical status at the time of initial and subsequent listing.</div></div><div><h3>Methods</h3><div>The United Network for Organ Sharing database was queried for adults listed for first-time isolated heart transplantation between October 18, 2018 and September 30, 2023. Patients delisted from their original transplant center due to relisting at another center were identified. Upon propensity score matching, waitlist and post-transplant outcomes were compared between single-listing and relisted patients. The same characteristics and center volume at the time of initial listing and subsequent relisting were compared. Center quality based on aggregated 1-year mortality was also assessed.</div></div><div><h3>Results</h3><div>Two hundred and seventeen patients were delisted and subsequently relisted. Upon propensity score matching, no significant differences were found between single-listing and relisted patients with regard to waitlist outcomes (all <em>p</em> &gt; 0.05). On subsequent listing, relisted patients had more severe functional limitations (10% vs 23%, <em>p</em> &lt; 0.001), higher status (<em>p</em> &lt; 0.001), and were more likely to be relisted at a higher volume (45% vs 73%, <em>p</em> &lt; 0.001) and better-performing transplant center (<em>p</em> = 0.017).</div></div><div><h3>Conclusions</h3><div>Although waitlist outcomes were similar between single-listing and relisted patients, at the time of relisting, patients were more likely to have severe functional limitations coinciding with higher listing statuses. Further work is needed to determine the underlying motivators for relisting.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"7 ","pages":"Article 100173"},"PeriodicalIF":0.0,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142703438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral versus central cannulation of VA-ECMO for primary graft dysfunction after heart transplantation: A systematic review and meta-analysis","authors":"Eduard Ródenas-Alesina MD ,&nbsp;Aleix Olivella MD ,&nbsp;Ani Orchanian-Cheff MiST ,&nbsp;Farid Foroutan PhD ,&nbsp;Yasbanoo Moayedi MD, MSc ,&nbsp;Vivek Rao MD, PhD ,&nbsp;Filio Billia MD, PhD ,&nbsp;Heather J. Ross MD, MHSc ,&nbsp;Ana Carolina Alba MD, PhD ,&nbsp;Natasha Aleksova MD, MSc","doi":"10.1016/j.jhlto.2024.100174","DOIUrl":"10.1016/j.jhlto.2024.100174","url":null,"abstract":"<div><h3>Background</h3><div>Severe primary graft dysfunction (PGD) after heart transplantation (HT) is a major cause of death and requires veno-arterial extracorporeal membrane oxygenation (VA-ECMO).</div></div><div><h3>Methods</h3><div>We conducted a systematic review and meta-analysis including studies of adult HT recipients who required VA-ECMO for PGD to determine whether a peripheral or central configuration was associated with higher mortality. The primary endpoints were short-term and one-year mortality. Secondary endpoints were VA-ECMO-related complications.</div></div><div><h3>Results</h3><div>Overall, we included 16 studies comprising 874 patients from 33 centers. Using a random-effects model, peripheral cannulation was associated with a nonsignificant reduction in short-term mortality (odds ratios [OR] = 0.73, 95% confidence interval [CI] = 0.41-1.28, I2 = 55.8%) and a significant reduction in 1-year mortality (OR = 0.60, 95%CI = 0.37-0.97, I2 = 35.9%). Peripheral cannulation decreased the risk of bleeding but increased the risk of limb ischemia and infection, with similar rates of stroke and need for renal replacement therapy. Overall, certainty of evidence was low.</div></div><div><h3>Conclusions</h3><div>With low certainty evidence, peripheral VA-ECMO cannulation may reduce short-term and 1-year mortality with lower bleeding rates but higher limb-related complications, supporting peripheral configuration in HT recipients with severe PGD.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"7 ","pages":"Article 100174"},"PeriodicalIF":0.0,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The state of combined thoracoabdominal triple-organ transplantation in the United States","authors":"Emily G. Dunbar BS ,&nbsp;Ye In Christopher Kwon BA ,&nbsp;Matthew Ambrosio MS ,&nbsp;Inna F. Tchoukina MD ,&nbsp;Keyur B. Shah MD ,&nbsp;David A. Bruno MD ,&nbsp;Walker A. Julliard MD ,&nbsp;Josue Chery MD ,&nbsp;Vigneshwar Kasirajan MD ,&nbsp;Zubair A. Hashmi MD","doi":"10.1016/j.jhlto.2024.100179","DOIUrl":"10.1016/j.jhlto.2024.100179","url":null,"abstract":"<div><h3>Background</h3><div>As triple-organ transplantation (TOT) has become more common, we evaluate patient characteristics, risk factors, and clinical outcomes of patients undergoing thoracoabdominal TOT.</div></div><div><h3>Methods</h3><div>This retrospective study utilized data from heart-lung-liver (HLL), heart-lung-kidney (HLK), heart-kidney-liver (HKL), and heart-kidney-pancreas (HKP) recipients from the United Network for Organ Sharing registry between 1989 and 2023. Recipient and donor characteristics and risk factors for mortality were analyzed using Cox regression hazard models. Recipient survival up to 10 years was analyzed using the Kaplan-Meier method.</div></div><div><h3>Results</h3><div>During the study period, 81 TOTs were performed (13 HLLs, 13 HLKs, 46 HKLs, and 9 HKPs). There were no statistically significant differences in long-term survival between TOTs (<em>p</em> = 0.13). However, HLL and HLK recipients had significantly worse (<em>p &lt;</em> 0.0001) and improved (<em>p &lt;</em> 0.0001) survival, respectively, when compared to heart-lung, isolated heart, and lung transplant recipients. HLK was associated with improved survival (hazard ratios [HR]: 0.22, <em>p</em> = 0.033). We found no differences in survival among HKL (<em>p</em> = 0.24) and HKP (<em>p</em> = 0.19) recipients compared to their dual- and single-organ counterparts. TOTs after 2007 (HR: 0.29, <em>p</em> = 0.003) were associated with improved survival, whereas increased recipient age (HR: 1.06, <em>p</em> = 0.037), estimated glomerular filtration rate (HR: 1.02, <em>p</em> = 0.005), and donor age (HR:1.05, <em>p</em> = 0.031) were associated with higher mortality.</div></div><div><h3>Conclusions</h3><div>The prevalence of TOTs has dramatically increased over the past decade. While overall survival between TOTs appears similar, adding a liver to a heart-lung transplant may be associated with a poorer prognosis compared to adding a kidney. A careful, multidisciplinary approach to patient selection and management remains paramount in optimizing outcomes for high-risk patients undergoing TOTs.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"7 ","pages":"Article 100179"},"PeriodicalIF":0.0,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142721684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Angiopoietin-2 and D-dimer add prognostic information to clinical risk in pulmonary arterial hypertension","authors":"Heather L. Clark ,&nbsp;Daniel Lachant ,&nbsp;Allison N. Light ,&nbsp;Deborah Haight ,&nbsp;Samia Lopia ,&nbsp;Nigel Mackman ,&nbsp;R. James White","doi":"10.1016/j.jhlto.2024.100178","DOIUrl":"10.1016/j.jhlto.2024.100178","url":null,"abstract":"<div><h3>Background</h3><div>Thrombosis and endothelial injury are pathologic hallmarks of pulmonary arterial hypertension (PAH). We aimed to evaluate whether markers of endothelial dysfunction and coagulation in the blood would provide insight into disease activity, treatment response, and outcomes in PAH.</div></div><div><h3>Methods</h3><div>We prospectively collected baseline and 3-month follow-up blood samples from treatment-naïve patients with PAH (<em>n</em> = 22) and those who had a clinical indication to intensify therapy (<em>n</em> = 19). In addition, we recruited 12 healthy people and clinically stable patients with PAH (<em>n</em> = 45) as controls who had 2 blood samples collected twice within 14 days. We generated platelet-free plasma and measured D-dimer, angiopoietin-2, thrombin time, soluble P-selectin, von Willebrand factor, and vascular endothelial growth factor. We assessed treatment response with Reveal Lite 2 scores (all patients had N-terminal-pro-brain natriuretic peptide, 6-minute walk, and functional class assessment at both visits) and followed clinical outcomes for 3 years.</div></div><div><h3>Results</h3><div>Angiopoietin-2 levels were elevated and fell in response to effective therapy (drop in Reveal Lite 2 score). At follow-up, persistently elevated angiopoietin-2 levels predicted clinical events and even identified low-risk participants who subsequently had events. D-dimer levels were also elevated in patients with PAH but did not change in response to therapy. Several other abnormalities in endothelial and platelet activation were identified (including elevated soluble P-selectin, elevated von Willebrand factor, and elevated vascular endothelial growth factor) but these did not change with treatment or predict outcome.</div></div><div><h3>Conclusions</h3><div>Angiopoietin-2 and D-dimer are elevated in patients with PAH and may add prognostic information to routine clinical assessment.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"7 ","pages":"Article 100178"},"PeriodicalIF":0.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142703435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to ‘‘Outcomes related to hospital characteristics of heart transplant centers: A national readmission database analysis’’ [JHLT Open (2024) 100085]","authors":"Farshad Amirkhosravi MD, MPH ,&nbsp;Duc T. Nguyen MD, PhD ,&nbsp;Roberto Secchi Del Rio MD ,&nbsp;Edward A. Graviss PhD, MPH ,&nbsp;Nadia Fida MD ,&nbsp;Ashrith Guha MD, MPH ,&nbsp;Cindy Martin MD ,&nbsp;Eric Suarez MD ,&nbsp;Lin-Chiang Philip Chou MD ,&nbsp;Arvind Bhimaraj MD, MPH","doi":"10.1016/j.jhlto.2024.100137","DOIUrl":"10.1016/j.jhlto.2024.100137","url":null,"abstract":"","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"6 ","pages":"Article 100137"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142586245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disturbed sleep after lung transplantation is associated with worse patient-reported outcomes and chronic lung allograft dysfunction","authors":"Aric A. Prather PhD ,&nbsp;Ying Gao MS ,&nbsp;Legna Betancourt BS ,&nbsp;Rose C. Kordahl BS ,&nbsp;Anya Sriram BS ,&nbsp;Chiung-Yu Huang PhD ,&nbsp;Steven R. Hays MD ,&nbsp;Jasleen Kukreja MD ,&nbsp;Daniel R. Calabrese MD ,&nbsp;Aida Venado MD ,&nbsp;Bhavya Kapse PhD ,&nbsp;John R. Greenland MD, PhD ,&nbsp;Jonathan P. Singer MD, MS","doi":"10.1016/j.jhlto.2024.100170","DOIUrl":"10.1016/j.jhlto.2024.100170","url":null,"abstract":"<div><h3>Background</h3><div>Many lung transplant recipients fail to derive the expected improvements in health-related quality of life (HRQL) and survival. Sleep may represent an important, albeit rarely examined, factor associated with lung transplant outcomes.</div></div><div><h3>Methods</h3><div>Within a larger cohort study, 141 lung transplant recipients completed the Medical Outcomes Study Sleep Problems Index (SPI) Revised scale along with a broader survey of patient-reported outcome (PRO) measures and frailty assessment. From the SPI, we also derived an insomnia-specific subscale. Potential perioperative risk factors for disturbed sleep were derived from medical records. We investigated associations between perioperative predictors on SPI and insomnia and associations between SPI and insomnia on PROs and frailty by linear regressions, adjusting for age, sex, and lung function. We evaluated the associations between SPI and insomnia on time to chronic lung allograft dysfunction (CLAD) and death using Cox models, adjusting for age, sex, and transplant indication.</div></div><div><h3>Results</h3><div>Post-transplant hospital length of stay &gt;30 days was associated with worse sleep by SPI and insomnia (SPI: <em>p</em> = 0.01; insomnia <em>p</em> = 0.02). Worse sleep by SPI and insomnia was associated with worse depression, cognitive function, HRQL, physical disability, health utilities, and Fried Frailty Phenotype frailty (all <em>p</em> &lt; 0.01). Those in the worst quartile of SPI and insomnia exhibited an increased risk of CLAD (hazard ratio [HR] 2.18; 95% confidence interval [CI]: 1.22-3.89; <em>p</em> = 0.01 for SPI and HR 1.96; 95%CI 1.09-3.53; <em>p</em> = 0.03 for insomnia). Worsening in SPI but not insomnia was also associated with mortality (HR: 1.29; 95%CI: 1.05-1.58; <em>p</em> = 0.01).</div></div><div><h3>Conclusions</h3><div>Poor sleep after lung transplant appears associated with PROs, frailty, CLAD, and death. Clarifying the nature of this association may have important screening implications.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"7 ","pages":"Article 100170"},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142721681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonlinear effect of body mass index on postoperative survival following isolated heart transplantation","authors":"Reid Dale PhD ,&nbsp;Nataliya Bahatyrevich MD, MS ,&nbsp;Matthew Leipzig BSc ,&nbsp;Maria Elizabeth Currie MD, PhD","doi":"10.1016/j.jhlto.2024.100172","DOIUrl":"10.1016/j.jhlto.2024.100172","url":null,"abstract":"<div><h3>Background</h3><div>Guidelines regarding recipient's body mass index (BMI) for heart transplant are evolving with variable cutoffs depending on the country and institution. It is imperative to provide updated nonlinear estimates of postoperative risk attributable to a recipient’s BMI to evaluate the relevance of existing cutoffs.</div></div><div><h3>Methods</h3><div>A total of 30,787 patients were analyzed from the United Network for Organ Sharing (UNOS) database. Patients receiving an isolated heart transplant ages 18 and older since 2010 were included. Overall survival was the primary outcome. A multivariate Cox proportional hazards model was applied and included a penalized smoothing spline term for recipient BMI and risk factors such as diabetes. We assessed the overall significance of the nonlinear penalized spline terms using an asymptotic Wald test.</div></div><div><h3>Results</h3><div>The cohort consisted of 662 (2.2%) BMI &lt;18.5, 9,359 (30%) BMI 18.5 to 24.9, 10,997 (36%) BMI 25 to 29.9, 9,550 (31%) BMI 30 to 39.9, and 206 (0.7%) BMI ≥40 patients. The nonlinear spline terms for recipient BMI were statistically significant (<em>p</em> &lt; 0.01). The hazard ratio (HR) appeared to grow linearly in BMI at an inflection point of BMI = 26. No inflection point was observed at either of the International Society for Heart and Lung Transplantation recommended cutoffs of BMI = 30 (HR 1.11, confidence interval [CI] 1.07-1.15) or BMI = 35 (HR 1.29, CI 1.24-1.37).</div></div><div><h3>Conclusions</h3><div>After multivariable adjustment, there is no sharp cutoff in survival risk at either BMI = 30 or BMI = 35. Unlike previously reported, postoperative survival risk grows approximately linearly in the BMI range from 26 to 40.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"7 ","pages":"Article 100172"},"PeriodicalIF":0.0,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142703439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of elexacaftor-tezacaftor-ivacaftor in lung transplantation for cystic fibrosis in the United States","authors":"Tahuanty A. Pena MD, MS ,&nbsp;Brittany Wright PharmD ,&nbsp;Kalpaj R. Parekh MBBS ,&nbsp;Julia Kleney-Tait MD, PhD","doi":"10.1016/j.jhlto.2024.100171","DOIUrl":"10.1016/j.jhlto.2024.100171","url":null,"abstract":"<div><h3>Background</h3><div>Cystic fibrosis (CF) is an autosomal recessive condition leading to progressive lung disease and often necessitating lung transplantation. Historically, CF has been one of the leading indications for lung transplants in the United States. The advent of CF transmembrane conductance regulator (CFTR) modulators, particularly elexacaftor-tezacaftor-ivacaftor (ETI), has significantly improved clinical outcomes for people with CF (pwCF), offering potential alterations in disease progression and transplantation needs.</div></div><div><h3>Methods</h3><div>Data on lung transplants performed in the United States since 1988 were retrieved from the Organ Procurement &amp; Transplantation Network. Custom reports were generated to compare the number of lung transplants and waitlist additions before and after ETI approval in 2019. The analysis focused on trends from 2009-2019 (pre-ETI) and 2021-2023 (post-ETI).</div></div><div><h3>Results</h3><div>The average annual lung transplants for CF decreased significantly from 243 (2009-2019) to 56.7 (2021-2023) post-ETI approval. Similarly, the average number of pwCF added to the lung transplant waitlist per year dropped from 295 to 55.6. Despite an overall increase in lung transplants and waitlist additions in the United States, the proportion involving pwCF has markedly declined post-ETI.</div></div><div><h3>Conclusions</h3><div>The introduction of ETI has dramatically reduced the need for lung transplants among pwCF, reflecting significant improvements in lung function and disease management. These findings underscore the transformative impact of CFTR modulators like ETI on the natural history of CF, highlighting the importance of continued advancements in precision medicine for genetic disorders. Future studies should investigate long-term outcomes and sustained trends in lung transplantation needs among pwCF.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"7 ","pages":"Article 100171"},"PeriodicalIF":0.0,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142651945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}